Enteral Albuterol for Treatment of Bradycardia in Acute SCI

Author Year
Country
Research Design
Sample Size

Methods Outcomes
Evans et al. (2014)
USA
Case Control
N=18
Population: Median age=49 yr (albuterol group), median age=51 yr (no-albuterol group); Gender: males=75%, females=25% (albuterol group), males=80%, females=20% (no-albuterol group); Level of injury: C5 or higher (n=7, albuterol group), C5 or higher (n=7, no-albuterol group); Severity of injury: median injury severity score (ISS)=36.5, AIS A-C (albuterol group), median ISS=26, AIS A-B (no albuterol group).

Intervention: Retrospective review of cervical SCI patients from a trauma center comparing those who were given (albuterol group) vs. those who were not given (no-albuterol group) enteral albuterol.

Outcome Measures: Incidence of bradycardia; Hospital days requiring chronotropic use; Total atropine administered.

Chronicity: Patients receiving albuterol were treated for a median of 5 days (range: 1-116 days); Patients not receiving albuterol were monitored for the initial 2 weeks of hospitalization.

  1. All patients developed bradycardia: time to bradycardic episode was 0-13 days in the albuterol group, and 0-23 days in the no-albuterol group.
  2. The median number of bradycardic episodes was significantly lower in patients receiving albuterol vs. those not receiving albuterol (1.8 vs. 4.3, p=0.08).
  3. Hospital days on chronotropic agents were significantly lower in patients receiving albuterol vs. those not receiving albuterol (0 vs. 5.5, p=0.05).
  4. The median total of atropine administered was significantly higher in patients not receiving albuterol vs. those receiving albuterol (1 mg vs. 0 mg, p=0.013).
top